Finance
Eli Lilly blows past quarterly estimates, hikes outlook as Zepbound and Mounjaro sales skyrocket
Lilly hiked its full-year sales outlook by $2 billion, and also raised its adjusted profit guidance.
C
CNBC
April 30, 2026·1 min read
GM
FinanceLilly hiked its full-year sales outlook by $2 billion, and also raised its adjusted profit guidance.
Original article
Eli Lilly blows past quarterly estimates, hikes outlook as Zepbound and Mounjaro sales skyrocket
Published by CNBC